Apr 01, 2021 7:59am EDT Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins
Mar 23, 2021 7:48am EDT Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021
Mar 17, 2021 7:00am EDT Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties
Mar 12, 2021 9:00am EST Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
Mar 10, 2021 4:00pm EST Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
Mar 03, 2021 7:00am EST Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET
Jan 20, 2021 4:00pm EST Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option
Jan 04, 2021 7:00am EST Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
Dec 17, 2020 7:00am EST Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma
